129 Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme
A.K. Bahl, S. Masson, Z. Malik, A. Birtle, S. Sundar, R. Jones, N. James, M. Mason, S. Kumar, D. Bottomley, A. Lydon, S. Chowdhury, J. Wylie, J. De BonoVolume:
11
Year:
2012
Language:
english
DOI:
10.1016/s1569-9056(12)60128-6
File:
PDF, 20 KB
english, 2012